The efficacy of off-label IL-5-modulating treatment in rare eosinophil-mediated diseases

Allergol Int. 2021 Apr;70(2):266-268. doi: 10.1016/j.alit.2020.10.001. Epub 2020 Oct 21.

¹ Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel; The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
² Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel. Electronic address: alonh@hadassah.org.il.
³ Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel.
⁴ Rheumatology Unit, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
⁵ Department of Dermatology, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
⁶ Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
⁷ Department of Pathology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
⁸ Faculty of Medicine, The Hebrew University, Jerusalem, Israel.

No abstract available

Publication types